AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21415073 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 341
Study 19357698 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and HCTZ 25 mg
Number of subjects: 2121
Study 19357698 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg and HCTZ 25 mg
Number of subjects: 2121
Study 19357698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2121
Study 19357698 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan-HCTZ
Number of subjects: 2121
Study 19357698 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan-HCTZ
Number of subjects: 2121
Study 17961200 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based cognitive-behavioural family intervention
Number of subjects: 60
Study 17961200 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 60
Study 15136065 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of circulating oxidized low-density lipoprotein (oxLDL)
Number of subjects: 238
Study 15136065 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of oxLDL levels
Number of subjects: 238
Study 15136065 — intervention group
Group type: EXPERIMENTAL
Intervention: Third quartile of oxLDL levels
Number of subjects: 238
Study 11340684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human DNase (rhDNase)
Number of subjects: 12
Study 11340684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9263304 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based skin cancer prevention lesson
Number of subjects: 0
Study 9263304 — intervention group
Group type: COMPARATOR
Intervention: Interactive sun safety fair
Number of subjects: 0
Study 8243793 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 12
Study 8243793 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12
Study 8243793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3517534 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle ear irrigation
Number of subjects: 220
Study 3517534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irrigation)
Number of subjects: 220
Study 30154254 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent retriever (SR) treatment with SVS present
Number of subjects: 217
Study 30154254 — intervention group
Group type: COMPARATOR
Intervention: Stent retriever (SR) treatment without SVS
Number of subjects: 217
Study 28646900 — intervention group
Group type: EXPERIMENTAL
Intervention: HUMSC-CM
Number of subjects: 68
Study 25555361 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Balance Board (WBB)
Number of subjects: 35
Study 23925452 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (up to 400 mg/day)
Number of subjects: 37
Study 23925452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 21830049 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration of sevoflurane based on SEDLine™ data
Number of subjects: 0
Study 21830049 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical criteria (control group)
Number of subjects: 0
Study 19685411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet associated with exercise training (DET)
Number of subjects: 38
Study 19685411 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 38
Study 19685411 — intervention group
Group type: COMPARATOR
Intervention: Control group (lean children)
Number of subjects: 38
Study 17910221 — intervention group
Group type: EXPERIMENTAL
Intervention: Futura Bond NR (self-etching adhesive)
Number of subjects: 24
Study 17910221 — intervention group
Group type: COMPARATOR
Intervention: Control (without application of a desensitizing agent)
Number of subjects: 24
Study 17910221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector (desensitizing treatment)
Number of subjects: 24
Study 17910221 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaSens (desensitizing treatment)
Number of subjects: 24
Study 17910221 — intervention group
Group type: EXPERIMENTAL
Intervention: Isodan (desensitizing treatment)
Number of subjects: 24
Study 17910221 — intervention group
Group type: EXPERIMENTAL
Intervention: Futura Bond NR (desensitizing treatment)
Number of subjects: 24
Study 17910221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (desensitizing treatment)
Number of subjects: 24
Study 15133865 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifid triple viable capsule (BIFICO) (1.26 g/d)
Number of subjects: 30
Study 15133865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 30
Study 15133865 — intervention group
Group type: EXPERIMENTAL
Intervention: BIFICO
Number of subjects: 30
Study 11134427 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diagnosis through neonatal screening
Number of subjects: 650341
Study 11134427 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnosis (control group)
Number of subjects: 650341
Study 9232049 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge package containing a manual breast pump only
Number of subjects: 763
Study 9232049 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge package containing a commercially prepared infant formula and a manual breast pump
Number of subjects: 763
Study 9232049 — intervention group
Group type: COMPARATOR
Intervention: Commercially prepared infant formula discharge package only (Control)
Number of subjects: 763
Study 9232049 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing formula samples at discharge from the hospital
Number of subjects: 763
Study 8333941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% fusidic acid viscous eye drops, self-administered four times daily for seven days before surgery
Number of subjects: 79
Study 8333941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert ophthalmic drops)
Number of subjects: 79
Study 3080285 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol (200 micrograms four times daily) with tolmetin (2000 mg/day, in four divided doses)
Number of subjects: 60
Study 3080285 — intervention group
Group type: COMPARATOR
Intervention: placebo with tolmetin (2000 mg/day, in four divided doses)
Number of subjects: 60
Study 3080285 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol with tolmetin
Number of subjects: 60
Study 2790669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 100
Study 2790669 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam
Number of subjects: 100
Study 2790669 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 100
Study 30823563 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-source food (ASF) consumption
Number of subjects: 355
Study 27862291 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 101
Study 27862291 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging with chromoendoscopy (CE)
Number of subjects: 101
Study 27862291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pCLE and CE
Number of subjects: 101
Study 26440754 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Planning (AP) intervention
Number of subjects: 1982
Study 26440754 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 1982
Study 24206547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Boluses (IB) - 20 mg propofol boluses on demand
Number of subjects: 192
Study 24206547 — intervention group
Group type: COMPARATOR
Intervention: Pump Continuous Infusion (PCI) - 3 mg/kg/h plus 20 mg boluses on demand
Number of subjects: 192
Study 22040007 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention consisting of individual counseling using motivational interviewing techniques
Number of subjects: 816
Study 22040007 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 816
Study 19593179 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract therapy
Number of subjects: 61
Study 19593179 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 61
Study 17229901 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (40 g soy protein, 118 mg isoflavones)
Number of subjects: 41
Study 17229901 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein
Number of subjects: 41
Study 17229901 — intervention group
Group type: COMPARATOR
Intervention: Gluten placebo
Number of subjects: 41
Study 12774015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine group (amantadine sulphate 100 mg twice daily orally)
Number of subjects: 400
Study 12774015 — intervention group
Group type: COMPARATOR
Intervention: Control group (IFN-alpha plus ribavirin)
Number of subjects: 400
Study 12774015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine group
Number of subjects: 400
Study 12774015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 12774015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine group (HCV genotype 1)
Number of subjects: 400
Study 12774015 — intervention group
Group type: COMPARATOR
Intervention: Control group (HCV genotype 1)
Number of subjects: 400
Study 10703678 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1200 IU of all‐rac‐alpha‐tocopheryl acetate taken 6 h before hemodialysis)
Number of subjects: 22
Study 10703678 — intervention group
Group type: COMPARATOR
Intervention: Control (without vitamin E supplementation)
Number of subjects: 22
Study 9216458 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily smokers
Number of subjects: 213
Study 9216458 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly alcohol consumption
Number of subjects: 213
Study 9216458 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 213
Study 9216458 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 213
Study 9216458 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference interval for P‐MDA
Number of subjects: 213
Study 8267669 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxerutins (900 mg/day for 12 weeks)
Number of subjects: 12
Study 8267669 — intervention group
Group type: COMPARATOR
Intervention: Troxerutin (900 mg/day for 12 weeks)
Number of subjects: 12
Study 8267669 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 12
Study 8267669 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxerutins
Number of subjects: 12
Study 3710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 15
Study 3710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 3710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 15
Study 3710631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29569219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (D2-receptor agonist)
Number of subjects: 0
Study 29569219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26683763 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus asunaprevir (ASV)
Number of subjects: 229
Study 24491193 — intervention group
Group type: EXPERIMENTAL
Intervention: Premonitory Urge to Tic Scale (PUTS)
Number of subjects: 122
Study 23840645 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake therapy (sleep deprivation) combined with light therapy and sleep time stabilisation
Number of subjects: 74
Study 23840645 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 74
Study 20617906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound gel
Number of subjects: 48
Study 20617906 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-cm-thick pad
Number of subjects: 48
Study 20617906 — intervention group
Group type: COMPARATOR
Intervention: 2-cm-thick pad
Number of subjects: 48
Study 18261193 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component alcohol use preventive intervention
Number of subjects: 5812
Study 18261193 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based programs
Number of subjects: 5812
Study 18261193 — intervention group
Group type: COMPARATOR
Intervention: Control condition ('prevention as usual')
Number of subjects: 5812
Study 18261193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention communities
Number of subjects: 5812
Study 15722280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound
Number of subjects: 33
Study 15722280 — intervention group
Group type: COMPARATOR
Intervention: Stress radiography
Number of subjects: 33
Study 11943634 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized salt
Number of subjects: 400
Study 9638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill running
Number of subjects: 53
Study 9638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill running
Number of subjects: 53
Study 9638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramarathon (67 km distance; 30 km downhill running)
Number of subjects: 53
Study 9638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpine long-distance cycling (230 km distance)
Number of subjects: 53
Study 7648158 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglyconate sutures
Number of subjects: 204
Study 7648158 — intervention group
Group type: COMPARATOR
Intervention: Polyglycolic acid sutures
Number of subjects: 204
Study 2554630 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine B 500 mg intravenously followed by packed red cell transfusion
Number of subjects: 24
Study 2554630 — intervention group
Group type: COMPARATOR
Intervention: Control group (only transfused)
Number of subjects: 24
Study 782774 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 1 mg/70 kg
Number of subjects: 104
Study 782774 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg/70 kg
Number of subjects: 104
Study 782774 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 4 mg/70 kg
Number of subjects: 104
Study 782774 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 40 mg/70 kg
Number of subjects: 104
Study 782774 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 80 mg/70 kg
Number of subjects: 104
Study 30415628 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (2 g twice daily, total daily dose 4 g)
Number of subjects: 8179
Study 30415628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8179
Study 29925712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% malic acid spray
Number of subjects: 70
Study 29925712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 70
Study 26572686 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg once daily plus PegIFN/RBV for 24 weeks
Number of subjects: 118
Study 26572686 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Number of subjects: 118
Study 24924261 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV plus irinotecan (n = 23)
Number of subjects: 51
Study 24924261 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV plus oxaliplatin (n = 28)
Number of subjects: 51
Study 24924261 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutation status
Number of subjects: 51
Study 22229837 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal sumatriptan
Number of subjects: 530
Study 19297310 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-9 diagnoses with somatization potential
Number of subjects: 1364
Study 19297310 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-rated somatization
Number of subjects: 1364
Study 17848678 — intervention group
Group type: EXPERIMENTAL
Intervention: CT findings for in situ carcinoma
Number of subjects: 46
Study 17848678 — intervention group
Group type: EXPERIMENTAL
Intervention: CT findings for invasive carcinoma
Number of subjects: 46
Study 17848678 — intervention group
Group type: EXPERIMENTAL
Intervention: CT for determining resectability
Number of subjects: 46
Study 17848678 — intervention group
Group type: EXPERIMENTAL
Intervention: CT for determining unresectability
Number of subjects: 46
Study 17848678 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy of CT
Number of subjects: 46
Study 14722645 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.28 g of glutamine per kg bodyweight per day intravenously for five days
Number of subjects: 40
Study 14722645 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.57 g of glutamine per kg bodyweight per day intravenously for five days
Number of subjects: 40
Study 14722645 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.86 g of glutamine per kg bodyweight per day intravenously for five days
Number of subjects: 40
Study 14722645 — intervention group
Group type: COMPARATOR
Intervention: 0 g of glutamine per kg bodyweight per day intravenously for five days (control)
Number of subjects: 40
Study 12201937 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL with diuresis (i.v. infusion of 500 ml normal saline containing 40 mg furosemide)
Number of subjects: 106
Study 12201937 — intervention group
Group type: COMPARATOR
Intervention: Standard ESWL
Number of subjects: 106
Study 9653697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of azithromycin
Number of subjects: 0
Study 9653697 — intervention group
Group type: COMPARATOR
Intervention: Standard course of erythromycin
Number of subjects: 0
Study 9653697 — intervention group
Group type: COMPARATOR
Intervention: Standard course of tetracycline (for sexual partners)
Number of subjects: 0
Study 9653697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of azithromycin (for patients)
Number of subjects: 0
Study 8581842 — intervention group
Group type: EXPERIMENTAL
Intervention: Local nasal immunotherapy (LNIT) with allergen in powder form
Number of subjects: 30
Study 8581842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2523787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (0.5 g x 3 daily)
Number of subjects: 10
Study 795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg i.v.)
Number of subjects: 5
Study 795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg, sublingual)
Number of subjects: 5
Study 795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg i.v.)
Number of subjects: 5
Study 795700 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamol (20 mg i.v.)
Number of subjects: 5
Study 795700 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml saline i.v.)
Number of subjects: 5
Study 31472812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-run, physician-supervised AF clinic
Number of subjects: 413
Study 31472812 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 413
Study 28267470 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker-based program (CHW arm)
Number of subjects: 1200
Study 28267470 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control arm)
Number of subjects: 1200
Study 25924844 — intervention group
Group type: EXPERIMENTAL
Intervention: E'Sevo-3%
Number of subjects: 61
Study 25924844 — intervention group
Group type: EXPERIMENTAL
Intervention: E'Sevo-4%
Number of subjects: 61
Study 25924844 — intervention group
Group type: EXPERIMENTAL
Intervention: E'Sevo-5%
Number of subjects: 61
Study 24113028 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral 100 mg enteric-coated aspirin
Number of subjects: 19383
Study 24113028 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 19383
Study 21437676 — intervention group
Group type: EXPERIMENTAL
Intervention: Operational multidisciplinary antibiotic team
Number of subjects: 17
Study 21437676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no operational team)
Number of subjects: 17
Study 19722768 — intervention group
Group type: EXPERIMENTAL
Intervention: Water birth delivery (experimental group)
Number of subjects: 106
Study 19722768 — intervention group
Group type: COMPARATOR
Intervention: Conventional delivery method (control group)
Number of subjects: 106
Study 17822526 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to reduce smoking, depression, and intimate partner violence during pregnancy
Number of subjects: 1070
Study 17822526 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1070
Study 17822526 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 1070
Study 15026104 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-front incentive (25 dollars gift card) with the first survey mailing
Number of subjects: 2100
Study 15026104 — intervention group
Group type: COMPARATOR
Intervention: Promised incentive (25 dollars gift card) on receipt of completed survey
Number of subjects: 2100
Study 15026104 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetrician-gynecologists (up-front incentive)
Number of subjects: 2100
Study 15026104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians (up-front incentive)
Number of subjects: 2100
Study 11490106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral amyloid angiopathy (CAA)
Number of subjects: 83
Study 11490106 — intervention group
Group type: COMPARATOR
Intervention: Hypertension (HTN)
Number of subjects: 83
Study 9164907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaxillary muscle-sparing closure of patent ductus arteriosus
Number of subjects: 10
Study 1772296 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol (400 micrograms)
Number of subjects: 25
Study 1772296 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 11541691 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TAS)
Number of subjects: 0
Study 11541691 — intervention group
Group type: COMPARATOR
Intervention: Promethazine and ephedrine (P/E)
Number of subjects: 0
Study 11541691 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine and dextroamphetamine (S/D)
Number of subjects: 0
Study 11541691 — intervention group
Group type: COMPARATOR
Intervention: Intramuscularly administered promethazine
Number of subjects: 0
Study 31967515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 125